Adenocarcinoma

Subtype terms (29)

More specific conditions that are subtypes of Adenocarcinoma in the MeSH hierarchy.

• Adenocarcinoma, Clear Cell

  28 drugs (22 approved, 6 experimental)

• Adenocarcinoma, Follicular

  1 drug approved

• Adenocarcinoma in Situ

  2 drugs approved

• Adenocarcinoma, Mucinous

  11 drugs approved

• Adenocarcinoma of Lung

  97 drugs (47 approved, 50 experimental)

• Adenocarcinoma, Papillary

  3 drugs (2 approved, 1 experimental)

• Adenocarcinoma, Scirrhous

  1 drug experimental

• Adenocarcinoma, Sebaceous
• Adrenocortical Carcinoma

  64 drugs (37 approved, 27 experimental)

• Carcinoid Tumor

  50 drugs (31 approved, 19 experimental)

• Carcinoma, Acinar Cell

  6 drugs (4 approved, 2 experimental)

• Carcinoma, Adenoid Cystic

  73 drugs (41 approved, 32 experimental)

• Carcinoma, Ductal

  9 drugs (7 approved, 2 experimental)

• Carcinoma, Endometrioid

  21 drugs (15 approved, 6 experimental)

• Carcinoma, Hepatocellular

  751 drugs (224 approved, 527 experimental)

• Carcinoma, Intraductal, Noninfiltrating

  38 drugs (29 approved, 9 experimental)

• Carcinoma, Islet Cell

  28 drugs (22 approved, 6 experimental)

• Carcinoma, Lobular

  6 drugs approved

• Carcinoma, Mucoepidermoid

  43 drugs (29 approved, 14 experimental)

• Carcinoma, Neuroendocrine

  68 drugs (38 approved, 30 experimental)

• Carcinoma, Renal Cell

  632 drugs (190 approved, 442 experimental)

• Carcinoma, Signet Ring Cell

  2 drugs approved

• Carcinoma, Skin Appendage
• Cholangiocarcinoma

  271 drugs (110 approved, 161 experimental)

• Choriocarcinoma

  29 drugs (25 approved, 4 experimental)

• Cystadenocarcinoma
• Eccrine Porocarcinoma
• Paget Disease, Extramammary

  21 drugs (17 approved, 4 experimental)

• Pulmonary Adenomatosis, Ovine

Drugs by status

Organizations